
Lawson Eng

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4701744/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	<scp>Outâ€ofâ€pocket</scp> costs associated with head and neck cancer treatment. Cancer Reports, 2022, 5, e1528.	0.6	10
2	The use of patient-reported outcomes in routine cancer care: preliminary insights from a multinational scoping survey of oncology practitioners. Supportive Care in Cancer, 2022, 30, 1427-1439.	1.0	27
3	Osteoradionecrosis in head and neck cancer patients: Risk factors and comparison of grading systems Journal of Clinical Oncology, 2022, 40, e18057-e18057.	0.8	Ο
4	Impact of age and frailty on acute care use during immune checkpoint inhibitor (ICI) treatment: A population-based study Journal of Clinical Oncology, 2022, 40, 12002-12002.	0.8	1
5	Internet and social media use in cancer patients: association with distress and perceived benefits and limitations. Supportive Care in Cancer, 2021, 29, 5273-5281.	1.0	16
6	Systemic Inflammatory Markers of Survival in Epidermal Growth Factor–Mutated Non–Small-Cell Lung Cancer: Single-Institution Analysis, Systematic Review, and Meta-analysis. Clinical Lung Cancer, 2021, 22, 390-407.	1.1	7
7	The Association of Antibiotic (ATB) exposure prior to immune checkpoint inhibitor (ICI) treatment on early emergency room and hospitalization utilization: A population-based study Journal of Clinical Oncology, 2021, 39, 304-304.	0.8	Ο
8	Reporting of tobacco use and impact on outcomes in cancer cooperative group clinical trials: A systematic scoping review Journal of Clinical Oncology, 2021, 39, 40-40.	0.8	1
9	Impact of antibiotic (ATB) exposure prior to immune checkpoint inhibitor (ICI) treatment on overall survival (OS): A population-based study Journal of Clinical Oncology, 2021, 39, 303-303.	0.8	1
10	Increasing Referrals of Patients With Gastrointestinal Cancer to a Cancer Rehabilitation Program: A Quality Improvement Initiative. JCO Oncology Practice, 2021, 17, e593-e602.	1.4	4
11	Investigating the Smoking Cessation Informational Needs of Cancer Patients and Informal Caregivers. Journal of Cancer Education, 2020, 35, 954-964.	0.6	5
12	Awareness of the Harms of Continued Smoking Among Cancer Survivors. Supportive Care in Cancer, 2020, 28, 3409-3419.	1.0	11
13	Age differences in patterns and confidence of using internet and social media for cancer-care among cancer survivors. Journal of Geriatric Oncology, 2020, 11, 1011-1019.	0.5	13
14	Measuring financial toxicity incurred after treatment of head and neck cancer: Development and validation of the Financial Index of Toxicity questionnaire. Cancer, 2020, 126, 4042-4050.	2.0	25
15	Cancer Patient-Reported Preferences and Knowledge for Liquid Biopsies and Blood Biomarkers at a Comprehensive Cancer Center. Cancer Management and Research, 2020, Volume 12, 1163-1173.	0.9	2
16	Health-related social media use and preferences of adolescent and young adult cancer patients for virtual programming. Supportive Care in Cancer, 2020, 28, 4789-4801.	1.0	14
17	The impact of tobacco retail density on overall survival (OS) in lung cancer survivors Journal of Clinical Oncology, 2020, 38, 12058-12058.	0.8	1
18	Comparing characteristics and outcomes of cancer to non-cancer patients admitted to general internal medicine (GIM) Journal of Clinical Oncology, 2020, 38, 21-21.	0.8	1

LAWSON ENG

#	Article	IF	CITATIONS
19	Comparing cancer survivors' perceptions on lifestyle behaviors between adolescent-young adult (AYA) and middle-aged patients (pts) Journal of Clinical Oncology, 2020, 38, 207-207.	0.8	0
20	Development and prospective evaluation of CAPLET, a cancer ambulatory patient physical function longitudinal evaluation tool for routine clinical practice. Supportive Care in Cancer, 2019, 27, 521-530.	1.0	3
21	Acceptability of Routine Evaluations Using Patient-Reported Outcomes of Common Terminology Criteria for Adverse Events and Other Patient-Reported Symptom Outcome Tools in Cancer Outpatients: Princess Margaret Cancer Centre Experience. Oncologist, 2019, 24, e1219-e1227.	1.9	14
22	Association of two <i>BRM</i> promoter polymorphisms and smoking status with malignant pleural mesothelioma risk and prognosis. Molecular Carcinogenesis, 2019, 58, 1960-1973.	1.3	1
23	Realâ€world health utility scores and toxicities to tyrosine kinase inhibitors in epidermal growth factor receptor mutated advanced nonâ€small cell lung cancer. Cancer Medicine, 2019, 8, 7542-7555.	1.3	14
24	Impact of immigration status on health behaviors and perceptions in cancer survivors. Cancer Medicine, 2019, 8, 2623-2635.	1.3	8
25	Patterns, perceptions and their association with changes in alcohol consumption in cancer survivors. European Journal of Cancer Care, 2019, 28, e12933.	0.7	12
26	Tobacco retail availability and tobacco cessation in lung and head and neck (HN) cancer survivors Journal of Clinical Oncology, 2019, 37, 11559-11559.	0.8	1
27	Predictors of financial toxicity among head and neck cancer patients: A prospective cohort study Journal of Clinical Oncology, 2019, 37, e18361-e18361.	0.8	1
28	Bone metastases as predictors of treatment response and rapidly progressive disease in NSCLC patients on PD-1/PD-L1 immune checkpoint inhibitors (ICI) Journal of Clinical Oncology, 2019, 37, e20667-e20667.	0.8	1
29	Implementation of a Novel Electronic Patient-Directed Smoking Cessation Platform for Cancer Patients: Interrupted Time Series Analysis. Journal of Medical Internet Research, 2019, 21, e11735.	2.1	15
30	Real-world characterization of patients with cancer admitted with immune-related adverse events (irAEs) Journal of Clinical Oncology, 2019, 37, 82-82.	0.8	0
31	Comparison of care patterns for hospitalized immune-related adverse events (irAEs) between melanoma patients on combination immune checkpoint inhibitor (ICI) therapy versus ICI monotherapy Journal of Clinical Oncology, 2019, 37, 85-85.	0.8	2
32	Myeloid immunosuppressive state as a predictor of rapidly progressive phenotype and poor survival in advanced non-small cell lung cancer (NSCLC) patients treated with PD-1/PD-L1 inhibitors Journal of Clinical Oncology, 2019, 37, e20594-e20594.	0.8	0
33	Impact of health behavior change on health utility (HU) and financial toxicity in head and neck cancer (HNC) survivors Journal of Clinical Oncology, 2019, 37, 11561-11561.	0.8	0
34	Comparing health utility scores, treatments, and outcomes in lung cancer patients with rare EGFR mutations with those with exon 19 deletion (del) and L858R mutations Journal of Clinical Oncology, 2019, 37, 102-102.	0.8	0
35	Impact of depression and anxiety on cancer patients' perceptions of lifestyle behaviors Journal of Clinical Oncology, 2019, 37, 141-141.	0.8	1
36	Perceptions of Continued Smoking and Smoking Cessation Among Patients With Cancer. Journal of Oncology Practice, 2018, 14, e269-e279.	2.5	35

LAWSON ENG

#	Article	IF	CITATIONS
37	Patterns, perceptions, and perceived barriers to physical activity in adult cancer survivors. Supportive Care in Cancer, 2018, 26, 3755-3763.	1.0	57
38	Cancer patient-reported knowledge and preferences for liquid biopsies and blood biomarkers at a comprehensive cancer centre Journal of Clinical Oncology, 2018, 36, 6587-6587.	0.8	0
39	Assessment of language needs and resource use among Canadian immigrant patients with cancer Journal of Clinical Oncology, 2018, 36, 77-77.	0.8	0
40	Cancer patient (pt) attitudes and preferences towards smoking status assessment Journal of Clinical Oncology, 2018, 36, 177-177.	0.8	1
41	Routine collection of EQ-5D-5L derived utility scores in a brain metastases clinic: Correlation with health-related quality of life (FACT-Br) Journal of Clinical Oncology, 2018, 36, 200-200.	0.8	1
42	Validation of micro <scp>RNA</scp> pathway polymorphisms in esophageal adenocarcinoma survival. Cancer Medicine, 2017, 6, 361-373.	1.3	11
43	Association of BRM promoter polymorphisms and esophageal adenocarcinoma outcome. Oncotarget, 2017, 8, 28093-28100.	0.8	5
44	Elimination of second-hand smoke (SHS) exposure after a lung or head and neck (HN) cancer diagnosis and subsequent patient smoking cessation Journal of Clinical Oncology, 2016, 34, 183-183.	0.8	1
45	Cancer patient awareness of the harms of continued smoking Journal of Clinical Oncology, 2016, 34, 10086-10086.	0.8	0
46	Cancer patients' interest and preferences for an inpatient smoking cessation program (SCP) Journal of Clinical Oncology, 2016, 34, 10090-10090.	0.8	0
47	The role of secondâ€hand smoke exposure on smoking cessation in non–tobaccoâ€related cancers. Cancer, 2015, 121, 2655-2663.	2.0	21
48	Lifestyle Behaviors in Elderly Cancer Survivors: A Comparison With Middle-Age Cancer Survivors. Journal of Oncology Practice, 2015, 11, e450-e459.	2.5	27
49	Discovery and validation of vascular endothelial growth factor (VEGF) pathway polymorphisms in esophageal adenocarcinoma outcome. Carcinogenesis, 2015, 36, 956-962.	1.3	7
50	Cancer patients' attitudes, knowledge, and preferences for smoking cessation (SC) Journal of Clinical Oncology, 2015, 33, 9581-9581.	0.8	0
51	Change in second-hand smoke exposure after a lung and head and neck cancer diagnosis and subsequent patient smoking cessation Journal of Clinical Oncology, 2015, 33, 9556-9556.	0.8	0
52	Second-Hand Smoke As a Predictor of Smoking Cessation Among Lung Cancer Survivors. Journal of Clinical Oncology, 2014, 32, 564-570.	0.8	59
53	Social and perceptual influences on alcohol consumption in cancer survivors Journal of Clinical Oncology, 2014, 32, 9575-9575.	0.8	0
54	VEGF pathway polymorphisms as prognostic and pharmacogenetic factors in cancer: a 2013 update. Pharmacogenomics, 2013, 14, 1659-1667.	0.6	13

LAWSON ENG

#	Article	lF	CITATIONS
55	Social environment, secondary smoking exposure, and smoking cessation among head and neck cancer patients. Cancer, 2013, 119, 2701-2709.	2.0	51
56	Assessment of accuracy of data obtained from patient-reported questionnaire (PRQ) compared to electronic patient records (EPR) in patients with lung cancer Journal of Clinical Oncology, 2013, 31, 40-40.	0.8	3
57	MicroRNA polymorphisms and esophageal cancer outcome Journal of Clinical Oncology, 2013, 31, 32-32.	0.8	1
58	Perceptions of benefits and harms of alcohol consumption as predictors of alcohol cessation in adult cancer survivors Journal of Clinical Oncology, 2013, 31, 9595-9595.	0.8	0
59	The role of social exposure to smoking on smoking cessation in adult cancer survivors Journal of Clinical Oncology, 2013, 31, 9536-9536.	0.8	0
60	Promoter polymorphisms of the SWI/SNF chromatin remodeling complex molecule, BRM, and esophageal adenocarcinoma outcome Journal of Clinical Oncology, 2013, 31, 4077-4077.	0.8	1
61	Comparing elderly and non-elderly adult cancer survivors: Differences in modifiable behaviours of smoking and alcohol cessation and physical activity Journal of Clinical Oncology, 2013, 31, 9551-9551.	0.8	0
62	Vascular Endothelial Growth Factor Pathway Polymorphisms as Prognostic and Pharmacogenetic Factors in Cancer: A Systematic Review and Meta-analysis. Clinical Cancer Research, 2012, 18, 4526-4537.	3.2	48
63	Use of online resources by patients with cancer: The Canadian experience Journal of Clinical Oncology, 2012, 30, 318-318.	0.8	2
64	Association of <i>p53 Arg72Pro</i> polymorphism and HPV status with the initiation, progression, and development of cervical cancer (CC): A meta-analysis Journal of Clinical Oncology, 2012, 30, 1597-1597.	0.8	1
65	Social environment as a predictor of smoking cessation and recidivism in lung cancer survivors Journal of Clinical Oncology, 2012, 30, 9032-9032.	0.8	0
66	Developing a comprehensive smoking cessation program in patients with lung cancer: The role of social smoking environments Journal of Clinical Oncology, 2012, 30, 75-75.	0.8	0
67	Bioinformatic analyses identifies novel protein-coding pharmacogenomic markers associated with paclitaxel sensitivity in NCI60 cancer cell lines. BMC Medical Genomics, 2011, 4, 18.	0.7	22